HIV-1 Peptide Vaccine, Microparticulate Monovalent

BIOLOGICAL3 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID), United Biomedical

Conditions

HIV Infections

Phase 1

A Phase I Trial To Evaluate the Safety and Immunogenicity of the UBI HIV-1MN PND Peptide Immunogen, Given by IM Injection, in Combination With the UBI Microparticulate Monovalent HIV-1 MN Branched Peptide Given Orally, in HIV-1 Uninfected Volunteers.

CompletedNCT00000846

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

Target: 36Updated: 2005-06-24

A Phase I/II Safety and Immunogenicity Trial of UBI Microparticulate Monovalent (HIV-1 MN) Branched Peptide Vaccine in HIV-1 Seronegative Human Subjects

CompletedNCT00002428

United BiomedicalHIV Infections

Updated: 2005-06-24

A Phase I Safety and Immunogenicity Trial of UBI Microparticulate Monovalent HIV-1 MN Peptide Immunogen in HIV-1 Seronegative Human Subjects

CompletedNCT00000798

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

Target: 32Updated: 2005-06-24